EXABLATE
Insightec · Decision date Mar 23, 2026
What did the FDA approve?
FDA records P150038/S041 as a supplement to PMA P150038, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Mar 23, 2026.
FDA approval order statement
Approval of the post-approval study (PAS) to comply with the conditions of approval outlined in our approval order for P150038/S037.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Neurology
- Decision date
- Mar 23, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P150038/S041
- Regulatory pathway
- PMA supplement
- Applicant
- Insightec
- Product code
- POH
- Decision code
- APPR
- Decision date
- Mar 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: MR-guided focused ultrasound system.
For the original device and its historical approval scope, see PMA P150038. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150038 · Original PMA
EXABLATE
P150038/S041 received
Application receipt date recorded by FDA.
P150038/S043 · Related supplement
Exablate Model 4000 System
P150038/S042 · Related supplement
Exablate Model 4000 Type 1.0 and 1.1 (Exablate Neuro; Exablate Prime)
P150038/S041 · FDA decision
Normal 180 Day Track No User Fee
P150038/S044 · Related supplement
Exablate Model 4000 System
Timeline entries are records held by MedtechLedger for P150038. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150038
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
EXABLATEP150038 | Insightec | PMA approval | Jul 11, 2016 | FDA |
Exablate Model 4000 SystemP150038/S043 | Insightec | PMA supplement | Jan 28, 2026 | FDA |
| Insightec | PMA supplement | Mar 5, 2026 | FDA | |
Exablate Model 4000 SystemP150038/S044 | Insightec | PMA supplement | Sep 16, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Insightec
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5 Nahum Heth St., Tirat Carmel, 39120
Sources and methodology
- Original FDA record: P150038/S041
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


